A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

This study is looking for adults aged 18 or older who have advanced non-small cell lung cancer that can't be removed by surgery or has spread. Your cancer must also have a specific gene change called a HER2 mutation (exons 19 or 20), which will be checked with a special test. You should not have received any previous treatment for your advanced lung cancer aimed at easing symptoms.

There are also some important health checks. Your heart should be working well, and vital organs like your kidneys and liver need to be healthy enough. Doctors will also check your overall health and how well you can go about your daily activities. There are some specific conditions that would mean you couldn't join, such as having certain other gene changes in your cancer, untreated brain tumours, or some other serious health problems like heart attacks recently or severe lung conditions in the past.

If you choose to take part, you would be assigned to receive either the new drug (trastuzumab deruxtecan) or a combination of standard treatments. You would have regular visits to the clinic for treatments, check-ups, and tests to see how you are doing and how the treatment is affecting your cancer. These tests might include blood tests, scans, and possibly heart function tests. The doctors will also ask you about your general health and any side effects you might be experiencing. The study will continue as long as the treatment is helping you and you are tolerating it well. The total duration for each person can vary, but there will be ongoing follow-up to monitor your health.